BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhai Y, Ye X, Hu F, Xu J, Guo X, Cao Y, Lin Z, Zhou X, Guo Z, He J. Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States. Front Cardiovasc Med 2021;8:735466. [PMID: 34646873 DOI: 10.3389/fcvm.2021.735466] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Zheng Y, Guo X, Chen C, Chi L, Guo Z, Liang J, Wei L, Chen X, Ye X, He J. Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database. Pharmaceuticals (Basel) 2023;16. [PMID: 36678594 DOI: 10.3390/ph16010098] [Reference Citation Analysis]
2 Facon T, Moreau P, Martin TG, Spicka I, Oriol A, Koh Y, Lim A, Mikala G, Rosiñol L, Yağci M, Cavo M, Yong K, Risse ML, Asset G, Schwab S, Martinez G. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. Hematol Oncol 2022;40:1020-9. [PMID: 35653225 DOI: 10.1002/hon.3038] [Reference Citation Analysis]
3 Jang HY, Lee HK, Kim CJ, Yoon SS, Kim IW, Oh JM. Carfilzomib's Real-World Safety Outcomes in Korea: Target Trial Emulation Study Using Electronic Health Records. Int J Environ Res Public Health 2022;19. [PMID: 36294140 DOI: 10.3390/ijerph192013560] [Reference Citation Analysis]
4 Wang Y, Cui C, Ren X, Dong X, Cui W. Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021. Front Cardiovasc Med 2022;9:988013. [PMID: 36312283 DOI: 10.3389/fcvm.2022.988013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Cui C, Ren X, Cui W, Wang Y. Immune-related interstitial lung disease adverse event following immune checkpoint inhibitors and immune checkpoint inhibitors plus anti-VEGF antibody/chemotherapy: A real-world study from 2014 to 2022 based on FAERS databases.. [DOI: 10.21203/rs.3.rs-2023720/v1] [Reference Citation Analysis]
6 Kawasaki A, Murakami H, Chou T, Matsushita M, Kizaki M. Post-marketing surveillance of carfilzomib in Japanese patients with relapsed or refractory multiple myeloma. Future Oncol 2022;18:2661-74. [PMID: 35815645 DOI: 10.2217/fon-2022-0259] [Reference Citation Analysis]
7 Zheng Y, Zhou W, Guo X, Chi L, Chen C, Guo Z, Liang J, Wei L, Chen X, Ye X, He J. Drug-induced Stevens-Johnson syndrome: a disproportionality analysis from the pharmacovigilance database of the World Health Organization. Expert Opin Drug Saf 2022. [PMID: 35196201 DOI: 10.1080/14740338.2022.2045946] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]